AP-HP, Hôpital Paul Brousse, Department of Virology, WHO Rubella NRL, 94804 Villejuif, France; Univ Paris-Sud, INSERM U1193, Villejuif, 94804 France; Groupe de Recherche sur les Infections pendant la Grossesse (GRIG), France.
J Clin Virol. 2018 May;102:34-38. doi: 10.1016/j.jcv.2018.02.006. Epub 2018 Feb 15.
Currently, rubella and congenital rubella has been eliminated or is becoming a rare disease in many countries that have implemented effective vaccination programs. In most of these countries, it is recommended and of major importance to screen childbearing age women in order to identify susceptible women and offer them vaccination before pregnancy or after delivery. Immunity to rubella virus (RV) is commonly determined by measuring rubella-specific IgG (RV-IgG). However, looking at literature, it is obvious that standardization of RV-IgG assays is not effective, with different levels of International Units per milliliter (IU/mL) reported for a same sample, and consequently different interpretations of the result. This situation leads to misinterpretation of results, sometimes causing adverse clinical outcomes. This article aimed to review several factors, such as the introduction of large-scale vaccination programs and changes in epidemiology of RV infection, along with the development of new technologies that have complicated appreciation of the immune status of patients. However, there is currently no evidence that these factors may be of any influence on rubella resurgence.
目前,许多实施了有效疫苗接种计划的国家已经消除或正在减少风疹和先天性风疹的发生。在这些国家中,建议并非常重要的是对育龄妇女进行筛查,以发现易感妇女,并在怀孕前或分娩后为她们接种疫苗。风疹病毒 (RV) 免疫力通常通过测量风疹特异性 IgG(RV-IgG)来确定。然而,从文献中可以明显看出,RV-IgG 检测的标准化效果并不理想,对于相同的样本,报告的国际单位/毫升 (IU/mL) 水平不同,因此对结果的解释也不同。这种情况导致结果的误读,有时会导致不良的临床后果。本文旨在综述一些因素,如大规模疫苗接种计划的引入和 RV 感染的流行病学变化,以及新技术的发展,这些因素使得对患者免疫状态的评估变得复杂。然而,目前没有证据表明这些因素可能会对风疹的再次流行产生影响。